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Pretreatment Depression as a
Prognostic Indicator of Survival
and Nutritional Status in Patients
With Head and Neck Cancer
Patients with head and neck cancer (HNC) often experi-
ence negative side effects of treatment such as oral dysfunc-
tion (eg, dry mouth, sticky saliva, or oral pain), swallowing
and speech problems, insomnia, and fatigue, which are
related to distress. A recent meta-analysis demonstrated a
pooled estimate of depression among patients with HNC
of 11% (95% confidence interval, 3%-34%) as measured
by diagnostic interviews and 20% (95% confidence inter-
val, 16%-25%) as measured by screening instruments.1
We read with great interest the study by Kim et al,2
who reported a significant association between pretreat-
ment depression (prevalence of 25% as measured by a
screening instrument) and survival in patients with HNC.
Among patients with cancer, previous studies also have
reported a significant association between depression and
survival.3,4 In fact, several hundred studies including
healthy community samples and disease-specific popula-
tions have shown that depression is associated with sur-
vival. A recent meta-analysis of 293 studies again
demonstrated that there is a significant association
between depression and excess mortality, but to our
knowledge there are only a few indications that this associ-
ation is stronger in community or specific patient sam-
ples.5 This meta-analysis also included 29 studies on
cancer, including one regarding HNC. Thus, the study by
Kim et al2 adds to the large amount of evidence regarding
a significant association between depression and survival.
However, it is not justified to state that “the results dem-
onstrate a close relation between pretreatment depression
and treatment outcome,” and therefore suggest that
depression is related to the outcome of treatment. The
study by Kim et al2 only confirms what has been found in
hundreds of earlier observational studies, nothing more.
However, to the best of our knowledge, the mecha-
nisms underlying the association between depression and
survival remain unclear and may well be cancer- or tu-
mor-specific.6,7 There are several reasons why depression
may enhance mortality risk in patients with HNC.
Depressed patients with HNC may use ineffective coping
strategies,8 and they are at risk of suicide.9 Unhealthy life-
style is a risk factor for excess mortality and in patients
with HNC continued alcohol use after diagnosis is
reported to have an adverse effect on survival.10 Empirical
evidence has suggested that tumor-related and patient-
related biomarkers of endocrine, immune, and autonomic
(dys)function also may be associated with depression and
survival. There is growing evidence that dysregulation of
hypothalamic-pituitary-adrenal axis function is associated
with depression and cancer survival. Neuroimmunologi-
cal explanations include increased immune responses and
increased levels of proinflammatory cytokines (eg, inter-
leukin 6), which were found to be associated with depres-
sion and survival among patients with HNC.11 Another
study has suggested that a common functional promoter
polymorphism of the neurotransmitter serotonin trans-
porter gene (serotonin transporter-linked polymorphic
region [5-HTTLPR]) may be associated with depression
in patients with HNC.12
Comprehensive insight into all these factors is nec-
essary to unravel these complex associations. To the best
of our knowledge, previous studies investigating the rela-
tion between depression and survival in patients with
(head and neck) cancer included relatively small cohorts
and/or a limited number of possible confounders. Conse-
quently, the association between depression and survival
among patients with cancer may have inadequately
adjusted for potentially relevant confounders. In the
Netherlands, a prospective, multicenter cohort study, the
Netherlands Quality of Life and Biomedical Cohort
Study in Head and Neck Cancer (NET-QUBIC) (avail-
able at: researchers.kubusproject.nl/home), currently is
ongoing. The data from this study will allow investiga-
tion of the course of depression and the association
between changes in depression and survival in patients
with HNC, controlling for cancer-related and treatment-
related, personal, biological, psychobehavioral, physical,
lifestyle-related, and social factors.
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Reply to Pretreatment Depression
as a Prognostic Indicator of
Survival and Nutritional Status
in Patients With Head and
Neck Cancer
We thank Verdonck-de Leeuw et al for their considerate
comments on our recent article published in Cancer.1 We
are pleased that our study has aroused such attention. Please
find our replies below to the issues raised in their review.
The comment that our findings concerning the rela-
tion between depression and survival have already been
reported in hundreds of earlier observational studies,
including those dealing with head and neck cancer
(HNC), and especially the mention that our study “only
confirms what has been found in hundreds of earlier
observational studies, nothing more” are incorrect and di-
minish the importance of our findings. We believe this
comment is based on a recent meta-analysis demonstrat-
ing that there is a significant association between depres-
sion and excess mortality.2 However, the final version of
this meta-analysis included only 13 studies reporting dif-
ferent outcomes in men and women out of 293 prospec-
tive studies examining mortality in patients with versus
those without depression.2 Moreover, the final analyses
involved samples collected from community or nursing
homes that treat mostly patients without cancer. There-
fore, we believe that there is a lack of appropriate referen-
ces to support the comments of Verdonck-de Leeuw et al.
As mentioned previously in our study,1 many reports
have indicated that depression influences survival in
patients with cancer.3,4 However, to the best of our knowl-
edge, the impact of pretreatment depression on the survival
and nutritional outcomes of patients with HNC has been
studied only rarely. A retrospective cohort of 35 patients
with HNC demonstrated that patients with depression had
higher levels of cancer recurrence and cancer-related death
compared with patients who were not depressed (50% vs
20%; P 5 .03).5 Our study also supports previous findings
indicating that depression can negatively influence the
nutritional status and quality of life of patients with
HNC.6,7 However, the most important aspect of our study
is that to our knowledge it is the first to demonstrate a close
relation between baseline depressive mood and survival
outcome in a large cohort of 241 patients with HNC who
were enrolled in a well-designed, prospective study.
Verdonck-de Leeuw et al also queried the potential
mechanisms underlying the association between depres-
sion and survival. As suggested previously, depression
among patients with cancer may result in ineffective cop-
ing strategies and unhealthy lifestyles, which in turn
increase the risk of suicide.8,9 In our study, the patients
with HNC with depression were more likely to have an
advanced initial stage of cancer, poor performance status,
and poor nutritional status with hypoalbuminemia.1
Although the clinical variables were associated with base-
line depression, they were not found to be independent
variables predicting overall and disease-free survival
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